Immunology of Varicella Immunization in the Elderly
9
Citation
26
Reference
10
Related Paper
Citation Trend
Abstract:
OBJECTIVE: To review the varicella-zoster virus (VZV) and herpes zoster disease and to summarize published reports on the use of the live-attenuated varicella zoster vaccine to enhance cell-mediated immunity in elderly individuals. DATA SOURCE: A MEDLINE search (1966–August 1999) for English-language clinical studies and review articles pertaining to VZV and the live-attenuated varicella vaccine was conducted; references obtained from these publications were subsequently reviewed for additional relevant articles. STUDY SELECTION AND DATA EXTRACTION: Representative clinical trials were summarized and relevant information was selected to assist in the understanding of VZV, the subsequent immune response, and the live-attenuated varicella vaccine. DATA SYNTHESIS: The physiologic, age-related decline in VZV cell–mediated immunity has been shown to be restored on administration of live-attenuated varicella vaccine. Various studies report serum anti-VZV antibody concentrations, and production of interferon-gamma were increased following vaccination. Concentrations subsequently returned to baseline one year after vaccination. Increase in responder cell frequency, a measure of cell-mediated immunity, has been reported to last up to four years after vaccination, at concentrations similar or superior to those observed following herpes zoster. CONCLUSIONS: Enhancement of cell-mediated immune response in elderly individuals through vaccination with live-attenuated varicella vaccine is a possible measure to protect this population from herpes zoster and to attenuate its complications. A summary of immunogenicity studies to identify the immune response to live-attenuated varicella vaccine in the elderly is presented. The absolute clinical significance, as well as appropriate administration guidelines of this prophylactic intervention, will become evident following forthcoming large, masked, placebo-controlled trials.Keywords:
Varicella zoster virus
Chickenpox Vaccine
Attenuated vaccine
Chicken Pox
Chicken Pox
Chickenpox Vaccine
Cite
Citations (11)
Oka/Merck varicella vaccine has been studied in this institution since 1981. Persistence of antibody for 6 to 8 years has been demonstrated; however, cases of chickenpox have been seen in immunized children. The severity of chickenpox in healthy children who have received Oka/Merck varicella vaccine since 1981 is described. All vaccinees who developed chickenpox-like rashes more than 6 weeks postimmunization were exammined. Of 2163 vaccinees, 164 were examined, of whom 114 had rashes consistent with chickenpox. When sera were available (46%), antibody studies uniformly confirmed varicella-zoster virus infection. Chickenpox occurred 2 to 96 months (median of 44 months) postimmunization. The range for the number of skin lesions was 1 to 285 (median 18) in seroconverters. Symptoms included itching in 39%, fever in 9%, headaches in 7%, lymphadenopathy in 3%, and malaise in 2%; 54% were asymptomatic, except for the rash. The median time to total healing was 5 days. The median time lost from school was 2 days. Thirteen of the children in whom infections developed had failed to seroconvert after immunization. Their infections were similar in severity to those of children who had seroconverted originally. When varicella was introduced into families as a result of chickenpox in an immunized family member (index case), the rate of secondary chickenpox among immunized siblings was 12.2%. Eleven such secondary cases were similar in severity to the 9 index cases. It is concluded that chickenpox is generally mild in previously immunized children.
Chicken Pox
Chickenpox Vaccine
Cite
Citations (172)
ABSTRACT Background Varicella (chickenpox) is a highly contagious disease caused by the varicella-zoster virus. Although typically a mild disease, varicella can cause complications leading to severe illness and even death. Safe and effective varicella vaccines are available. The Joint Committee on Vaccination and Immunisation is planning to review the evidence regarding the introduction of varicella vaccine into the UK’s routine childhood immunisation schedule. Objectives To explore UK healthcare professionals’ (HCPs) knowledge and attitudes towards varicella vaccination, its introduction to the UK routine childhood immunisation schedule, and their preferences for how it should be delivered. Design We conducted an online cross-sectional survey exploring HCPs’ attitudes towards varicella, varicella vaccine, and their preferences for delivery of the vaccine between August and September 2022. Participants 91 HCPs working in the UK (96.7% female, 3.3% male, mean age 48.7 years). Results General vaccine attitudes in this group were very positive. Gaps in knowledge about varicella were revealed: 21.0% of respondents disagreed or were unsure that chickenpox can cause serious complications, while 41.8% were unsure or did not believe chickenpox was serious enough to vaccinate against. After receiving some basic information about chickenpox and the vaccine, almost half of the HCPs (47.3%) in our survey would prefer to administer the varicella vaccine combined with MMR. Conclusions Given the positive influence of HCPs on parents’ decisions to vaccinate their children, it is important to understand HCPs’ views regarding the introduction of varicella vaccine into the routine schedule. Our findings highlighted areas for training and HCPs’ preferences which will have implications for policy and practice should the vaccine be introduced.
Chicken Pox
Chickenpox Vaccine
Vaccination schedule
Cite
Citations (0)
Varicella–zoster virus is the cause of both varicella (chickenpox) and herpes zoster (shingles). A live attenuated varicella vaccine was developed in Japan in 1974, and in 1995 it was approved for use in the United States. The policy of universal vaccination of susceptible children and adults has had a profound effect on the epidemiology of varicella. Its effect on the epidemiology of zoster remains to be seen, in part because of the long delay between primary infection with varicella–zoster virus and the subsequent occurrence of zoster.Before varicella vaccine was introduced, chickenpox developed in approximately 4 million persons, most of . . .
Chicken Pox
Shingles
Varicella zoster virus
Chickenpox Vaccine
Cite
Citations (71)
Chicken Pox
Chickenpox Vaccine
Cite
Citations (0)
Chicken Pox
Chickenpox Vaccine
Cite
Citations (1)
Chicken Pox
Chickenpox Vaccine
Cite
Citations (1)
Varicella, commonly known as chickenpox is an acute and highly infectious disease, which is caused by the varicella zoster virus Varicella. The two chickenpox vaccines available in the UK are Varilrix and Varivax but are not included in the routine childhood vaccination scheme unless they are immunocompromised ( Gov.uk, 2018 ; PHE, 2019 ). The varicella vaccination has been associated with a dramatic reduction in chickenpox cases in countries such as the United States, where every child can be vaccinated ( Seward et al, 2002 ). Johnston et al (1997) ; however, suggest that approximately 2–3% of patients vaccinated per year can develop a mild form of chickenpox regardless of the vaccine given. The Joint Committee on Vaccination and Immunisation (2010) has not recommended it as part of the national immunisation programme but nearly a decade later perhaps it is time to revisit this topic.
Chicken Pox
Chickenpox Vaccine
Cite
Citations (1)
Varicella (chickenpox) is a highly contagious disease caused by the varicella-zoster virus. Although typically mild, varicella can cause complications leading to severe illness and even death. Safe and effective varicella vaccines are available. The Joint Committee on Vaccination and Immunisation has reviewed the evidence and recommended the introduction of varicella vaccine into the UK's routine childhood immunisation schedule. To explore UK healthcare professionals' (HCPs) knowledge and attitudes towards varicella vaccination, its introduction to the UK routine childhood immunisation schedule, and their preferences for how it should be delivered. We conducted an online cross-sectional survey exploring HCPs' attitudes towards varicella, varicella vaccine, and their preferences for delivery of the vaccine between August and September 2022 prior to the recommendation that varicella vaccine should be introduced. 91 HCPs working in the UK (81 % nurses/health visitors, 9 % doctors, 10 % researcher/other, mean age 48.7 years). All respondents agreed or strongly agreed that vaccines are important for a child's health. However, only 58% agreed or strongly agreed that chicken pox was a disease serious enough to warrant vaccination. Gaps in knowledge about varicella were revealed: 21.0% of respondents disagreed or were unsure that chickenpox can cause serious complications, while 41.8% were unsure or did not believe chickenpox was serious enough to vaccinate against. After receiving some basic information about chickenpox and the vaccine, almost half of the HCPs (47.3%) in our survey would prefer to administer the varicella vaccine combined with MMR. Given the positive influence of HCPs on parents' decisions to vaccinate their children, it is important to understand HCPs' views regarding the introduction of varicella vaccine into the routine schedule. Our findings highlighted areas for training and HCPs' preferences which will have implications for policy and practice when the vaccine is introduced.
Chicken Pox
Chickenpox Vaccine
Vaccination schedule
Cite
Citations (2)